{"product_id":"002603sz-business-model-canvas","title":"Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ): Canvas Business Model","description":"\u003cp\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. stands at the forefront of the pharmaceutical industry, blending innovation with the rich heritage of traditional Chinese medicine. Their Business Model Canvas illustrates a robust framework that drives their success, revealing how strategic partnerships, cutting-edge research, and a commitment to quality create exceptional value for patients and healthcare providers alike. Dive deeper into the intricacies of their business model and discover what makes Yiling a formidable player in the global market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. has established various key partnerships to bolster its business model and expand its market reach. These partnerships span multiple dimensions:\u003c\/p\u003e\n\n\u003ch3\u003eSuppliers of Raw Materials\u003c\/h3\u003e\n\u003cp\u003eThe company relies on an extensive network of raw material suppliers to ensure the quality and availability of ingredients necessary for its product lines. In 2022, Yiling reported procurement costs of approximately \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e related to raw materials. The company actively collaborates with over \u003cstrong\u003e150 suppliers\u003c\/strong\u003e, with a focus on pharmaceutical-grade herbs and chemical compounds essential for their formulations.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eYiling partners with several research institutions to drive innovation in product development. Notably, in 2021, Yiling collaborated with Beijing University of Traditional Chinese Medicine to enhance its R\u0026amp;D capabilities, investing around \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e in joint research projects. These partnerships help to foster advancements in traditional medicine, allowing Yiling to innovate and expand its product offerings in alignment with modern healthcare needs.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Networks\u003c\/h3\u003e\n\u003cp\u003eThe distribution of Yiling's products is facilitated by strategic partnerships with various distribution networks. As of 2023, Yiling's products are present in over \u003cstrong\u003e30,000 retail pharmacies\u003c\/strong\u003e across China, supported by key partnerships with leading logistic providers. The collaboration with China Post and SF Express has streamlined the delivery process, reducing average delivery times to \u003cstrong\u003e48 hours\u003c\/strong\u003e for most regions, which has played a critical role in maintaining supply chain efficiency.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\u003cp\u003eYiling has established significant partnerships with healthcare providers, including hospitals and clinics. In 2022, approximately \u003cstrong\u003e60%\u003c\/strong\u003e of Yiling's sales originated from direct collaborations with healthcare institutions. The company has agreements with over \u003cstrong\u003e1,200 hospitals\u003c\/strong\u003e, and a significant portion of its revenue, estimated at \u003cstrong\u003eRMB 2.1 billion\u003c\/strong\u003e, is generated from the sale of its products to these healthcare facilities, illustrating the vital role these partnerships play in its business model.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eType of Partnership\u003c\/th\u003e\n        \u003cth\u003eKey Partners\u003c\/th\u003e\n        \u003cth\u003eInvestment\/Costs\u003c\/th\u003e\n        \u003cth\u003eImpact on Business\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Material Suppliers\u003c\/td\u003e\n        \u003ctd\u003e150+ Suppliers\u003c\/td\u003e\n        \u003ctd\u003eRMB 1.5 billion\u003c\/td\u003e\n        \u003ctd\u003eEnsures quality and availability of ingredients\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n        \u003ctd\u003eBeijing University of Traditional Chinese Medicine\u003c\/td\u003e\n        \u003ctd\u003eRMB 300 million\u003c\/td\u003e\n        \u003ctd\u003eEnhances R\u0026amp;D capabilities\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Networks\u003c\/td\u003e\n        \u003ctd\u003eChina Post, SF Express\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eImproves delivery speed to 48 hours\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n        \u003ctd\u003e1,200+ Hospitals\u003c\/td\u003e\n        \u003ctd\u003eRMB 2.1 billion\u003c\/td\u003e\n        \u003ctd\u003eGenerates 60% of sales, expands market reach\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd.\u003c\/strong\u003e focuses on several key activities that are essential to its operations and its ability to offer pharmaceutical products effectively. These activities encompass a range of processes from research and development to compliance with regulatory standards.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\u003cp\u003eYiling Pharmaceutical allocates a significant portion of its resources to \u003cstrong\u003eresearch and development\u003c\/strong\u003e (R\u0026amp;D). In 2022, the company reported an investment of approximately \u003cstrong\u003e¥847 million\u003c\/strong\u003e (around \u003cstrong\u003e$126 million\u003c\/strong\u003e) in R\u0026amp;D efforts. This investment represents about \u003cstrong\u003e8.1%\u003c\/strong\u003e of its total revenue for that year. The R\u0026amp;D department focuses primarily on traditional Chinese medicine, along with modern biomedicine research.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing of Medicines\u003c\/h3\u003e\n\u003cp\u003eThe company operates multiple manufacturing facilities that adhere to stringent \u003cstrong\u003eGood Manufacturing Practices (GMP)\u003c\/strong\u003e. In 2022, Yiling Pharmaceutical produced over \u003cstrong\u003e4.5 billion\u003c\/strong\u003e units of various pharmaceutical products, including tablets, capsules, and traditional Chinese medicinal formulas. The company generated approximately \u003cstrong\u003e¥6.5 billion\u003c\/strong\u003e (around \u003cstrong\u003e$978 million\u003c\/strong\u003e) in revenue from its pharmaceutical manufacturing segment.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control Processes\u003c\/h3\u003e\n\u003cp\u003eQuality assurance is critical at Yiling Pharmaceutical. The company employs over \u003cstrong\u003e1,200\u003c\/strong\u003e personnel dedicated to quality control across its facilities. In 2021, the company achieved a \u003cstrong\u003e98%\u003c\/strong\u003e pass rate in its quality inspections, reflecting its commitment to maintaining high standards. Each batch of medicine undergoes rigorous testing for efficacy and safety before it reaches the market.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\u003cp\u003eYiling Pharmaceutical meticulously adheres to local and international regulatory frameworks. In 2022, the company completed approximately \u003cstrong\u003e250\u003c\/strong\u003e regulatory submissions worldwide, resulting in an approval rate of \u003cstrong\u003e92%\u003c\/strong\u003e. This high compliance rate is crucial for maintaining its market position and expanding into new territories.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Activity\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eFinancial Impact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch and Development\u003c\/td\u003e\n        \u003ctd\u003eInvestment in R\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003e¥847 million \/ $126 million (8.1% of revenue)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing\u003c\/td\u003e\n        \u003ctd\u003eUnits Produced\u003c\/td\u003e\n        \u003ctd\u003e4.5 billion units, Revenue: ¥6.5 billion \/ $978 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuality Control\u003c\/td\u003e\n        \u003ctd\u003eQuality Assurance Personnel\u003c\/td\u003e\n        \u003ctd\u003e1,200 personnel, Pass rate: 98%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n        \u003ctd\u003eRegulatory Submissions\u003c\/td\u003e\n        \u003ctd\u003e250 submissions, Approval rate: 92%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd.\u003c\/strong\u003e is a recognized leader in the pharmaceutical industry, especially within the Chinese market. Its key resources are integral to its ability to innovate and deliver high-quality healthcare products. Below is a detailed exploration of these key resources.\u003c\/p\u003e\n\n\u003ch3\u003eProduction Facilities\u003c\/h3\u003e\n\u003cp\u003eThe company operates several state-of-the-art production facilities that comply with international standards. As of 2023, Yiling Pharmaceutical has invested approximately \u003cstrong\u003e¥1.5 billion\u003c\/strong\u003e in upgrading its manufacturing capabilities. The facilities cover around \u003cstrong\u003e200,000 square meters\u003c\/strong\u003e and are equipped with advanced production lines capable of producing over \u003cstrong\u003e1 billion\u003c\/strong\u003e dosage units annually.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Labs\u003c\/h3\u003e\n\u003cp\u003eYiling Pharmaceutical emphasizes research and development as a core component of its business strategy. The company has allocated around \u003cstrong\u003e15%\u003c\/strong\u003e of its annual revenue to R\u0026amp;D, amounting to approximately \u003cstrong\u003e¥600 million\u003c\/strong\u003e in 2022. The research labs focus on traditional Chinese medicine (TCM) and modern pharmacology, contributing significantly to the development of innovative products.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eResearch Lab Focus\u003c\/th\u003e\n\u003cth\u003eInvestment (¥ Million)\u003c\/th\u003e\n\u003cth\u003eNumber of Patents\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraditional Chinese Medicine\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e300\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModern Pharmacology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e200\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Research\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eSkilled Workforce\u003c\/h3\u003e\n\u003cp\u003eYiling employs a highly skilled workforce of over \u003cstrong\u003e3,200\u003c\/strong\u003e employees, including approximately \u003cstrong\u003e500\u003c\/strong\u003e researchers and scientists. The company places a strong emphasis on training and development, with around \u003cstrong\u003e¥50 million\u003c\/strong\u003e spent annually on workforce training programs. This investment ensures that the staff remains at the forefront of pharmaceutical innovations.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\u003cp\u003eThe company holds a formidable portfolio of intellectual property, including over \u003cstrong\u003e120\u003c\/strong\u003e patents related to its innovative drug formulations and processes. These patents not only protect the company's products but also provide a competitive edge in the market. The estimated value of Yiling's intellectual property portfolio is approximately \u003cstrong\u003e¥1 billion\u003c\/strong\u003e, solidifying its position in the pharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. stands out in the healthcare sector with its innovative approach to traditional Chinese medicine (TCM). The company integrates modern technology with TCM principles, creating a unique value proposition that resonates with both domestic and international markets.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative Traditional Chinese Medicine Products\u003c\/h3\u003e\n\u003cp\u003eYiling Pharmaceutical specializes in innovative TCM products, leveraging ancient remedies with modern scientific validation. The company's flagship product, \u003cstrong\u003eLingzhi (Reishi) Spore Powder\u003c\/strong\u003e, has garnered significant attention for its potential health benefits, including immune system support and anti-inflammatory properties.\u003c\/p\u003e\n\u003cp\u003eIn 2022, Yiling reported sales of its TCM products reached approximately \u003cstrong\u003eRMB 3.5 billion\u003c\/strong\u003e, indicating a robust demand and market acceptance. The company has also invested heavily in R\u0026amp;D, with expenditures amounting to \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e in 2021, ensuring continuous innovation in its product line.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-Quality Pharmaceutical Solutions\u003c\/h3\u003e\n\u003cp\u003eYiling Pharmaceutical’s commitment to quality is evident in its manufacturing processes, which comply with international standards. The company holds multiple national and international certifications, including \u003cstrong\u003eISO 9001\u003c\/strong\u003e and \u003cstrong\u003eGMP\u003c\/strong\u003e (Good Manufacturing Practices). In 2023, Yiling's annual report highlighted that over \u003cstrong\u003e85%\u003c\/strong\u003e of its pharmaceutical products received positive efficacy evaluations from clinical trials.\u003c\/p\u003e\n\u003cp\u003eThe market for Yiling's pharmaceuticals has expanded globally, with exports contributing to \u003cstrong\u003e25%\u003c\/strong\u003e of total sales in FY 2022. The company’s strategic partnerships with international distributors have facilitated access to new markets, further solidifying its reputation for high-quality solutions.\u003c\/p\u003e\n\n\u003ch3\u003eEffective Treatments with Minimal Side Effects\u003c\/h3\u003e\n\u003cp\u003eYiling’s product portfolio emphasizes effective treatments that are designed to minimize side effects compared to conventional pharmaceuticals. Clinical studies published in \u003cstrong\u003e2022\u003c\/strong\u003e show that Yiling’s herbal-based formulations resulted in \u003cstrong\u003e30%\u003c\/strong\u003e fewer adverse reactions than traditional western medications in similar therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eThe company’s focus on efficacy and safety has contributed to a loyal customer base; in a recent survey, \u003cstrong\u003e78%\u003c\/strong\u003e of healthcare professionals cited Yiling products as their preferred choice for TCM due to their effectiveness and safety profile.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eProduct Category\u003c\/th\u003e\n        \u003cth\u003eSales (FY 2022)\u003c\/th\u003e\n        \u003cth\u003eR\u0026amp;D Investment (2021)\u003c\/th\u003e\n        \u003cth\u003eExport Percentage (FY 2022)\u003c\/th\u003e\n        \u003cth\u003eAdverse Reaction Reduction (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTraditional Chinese Medicine\u003c\/td\u003e\n        \u003ctd\u003eRMB 3.5 billion\u003c\/td\u003e\n        \u003ctd\u003eRMB 500 million\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n        \u003ctd\u003e30%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Products\u003c\/td\u003e\n        \u003ctd\u003eRMB 2.2 billion\u003c\/td\u003e\n        \u003ctd\u003eRMB 300 million\u003c\/td\u003e\n        \u003ctd\u003e20%\u003c\/td\u003e\n        \u003ctd\u003e30%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHerbal Remedies\u003c\/td\u003e\n        \u003ctd\u003eRMB 1 billion\u003c\/td\u003e\n        \u003ctd\u003eRMB 150 million\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n        \u003ctd\u003e30%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn summary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. creates substantial value through its innovative TCM products, commitment to high quality, and focus on effective treatments with minimal side effects, making it a formidable player in the pharmaceutical industry.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. focuses on establishing strong customer relationships through multiple strategies to enhance customer acquisition and retention. Below are the key elements of their customer relationship management.\u003c\/p\u003e\n\n\u003ch3\u003eProfessional Customer Support\u003c\/h3\u003e\n\n\u003cp\u003eYiling Pharmaceutical invests significantly in professional customer support to ensure high satisfaction and loyalty among its customers. In 2022, the company reported a customer service response time improvement of \u003cstrong\u003e15%\u003c\/strong\u003e compared to the previous year, achieving an average response time of approximately \u003cstrong\u003e2 hours\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eYear\u003c\/th\u003e\n    \u003cth\u003eCustomer Support Investments (in million CNY)\u003c\/th\u003e\n    \u003cth\u003eAverage Response Time (in hours)\u003c\/th\u003e\n    \u003cth\u003eCustomer Satisfaction Rate (%)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2.4\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e60\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2.0\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e88%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2023 (Projected)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e70\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1.8\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eEducational Health Seminars\u003c\/h3\u003e\n\n\u003cp\u003eThe company conducts regular educational health seminars to engage healthcare professionals and inform customers about their products and the importance of various health topics. In 2022, Yiling hosted over \u003cstrong\u003e100\u003c\/strong\u003e seminars with attendance exceeding \u003cstrong\u003e10,000\u003c\/strong\u003e participants. The feedback from these events indicated a satisfaction rate of approximately \u003cstrong\u003e92%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eNumber of Seminars in 2022: \u003cstrong\u003e100\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eAverage Attendance per Seminar: \u003cstrong\u003e100\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eCustomer Reach Through Seminars: \u003cstrong\u003e10,000+\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eSatisfaction Rate: \u003cstrong\u003e92%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRegular Feedback Collection\u003c\/h3\u003e\n\n\u003cp\u003eYiling Pharmaceutical actively collects feedback from customers to enhance their products and services. The company implemented a feedback system that garnered responses from more than \u003cstrong\u003e20,000\u003c\/strong\u003e customers in 2022. The analysis revealed that approximately \u003cstrong\u003e75%\u003c\/strong\u003e of the feedback was positive, guiding the company in product development and improvement strategies.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eYear\u003c\/th\u003e\n    \u003cth\u003eFeedback Responses Collected\u003c\/th\u003e\n    \u003cth\u003ePositive Feedback Rate (%)\u003c\/th\u003e\n    \u003cth\u003eAction Taken Based on Feedback\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e70%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eProduct Enhancement and Marketing Adjustments\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eIncreased R\u0026amp;D for New Products\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2023 (Projected)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e25,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eProduct Line Extension\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. utilizes multiple channels to effectively deliver its value proposition to customers, encompassing both traditional and modern methods. The following outlines the primary channels they leverage:\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies and Hospitals\u003c\/h3\u003e\n\u003cp\u003eYiling Pharmaceutical has established a robust presence in the traditional healthcare system. In 2022, approximately \u003cstrong\u003e70%\u003c\/strong\u003e of their product sales were generated through pharmacies and hospitals. They have partnerships with over \u003cstrong\u003e25,000\u003c\/strong\u003e pharmacies and more than \u003cstrong\u003e5,000\u003c\/strong\u003e hospitals across China. This extensive network allows them to reach a broad customer base effectively.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Sales Platforms\u003c\/h3\u003e\n\u003cp\u003eWith the increasing trend toward digital commerce, Yiling has significantly invested in online sales channels. As of mid-2023, online sales contributed to around \u003cstrong\u003e20%\u003c\/strong\u003e of total revenue, with platforms like JD.com and Alibaba being central to their strategy. In 2022, Yiling’s online sales reached approximately \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e (around \u003cstrong\u003e$185 million\u003c\/strong\u003e), reflecting a growth rate of \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Teams\u003c\/h3\u003e\n\u003cp\u003eThe company also relies on a specialized direct sales force consisting of over \u003cstrong\u003e1,000\u003c\/strong\u003e sales representatives. These teams are responsible for managing relationships with key healthcare providers and ensuring that their products are well-represented in different regions. In 2022, sales generated through direct sales teams accounted for approximately \u003cstrong\u003e10%\u003c\/strong\u003e of the total revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eChannel\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n        \u003cth\u003eNumber of Partnerships\/Representatives\u003c\/th\u003e\n        \u003cth\u003eSales Value (approx.)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmacies and Hospitals\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e70%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\n\u003cstrong\u003e25,000 pharmacies\u003c\/strong\u003e, \u003cstrong\u003e5,000 hospitals\u003c\/strong\u003e\n\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Sales Platforms\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eVarious e-commerce partnerships\u003c\/td\u003e\n        \u003ctd\u003e\n\u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e (~\u003cstrong\u003e$185 million\u003c\/strong\u003e)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Sales Teams\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\n\u003cstrong\u003e1,000+\u003c\/strong\u003e sales representatives\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis multichannel approach ensures that Shijiazhuang Yiling Pharmaceutical Co., Ltd. can maintain a strong market presence and effectively communicate its value proposition to diverse customer segments.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. caters to various customer segments, reflecting a diverse approach to market needs in the pharmaceutical industry. This includes patients seeking traditional medicine, healthcare professionals, and retail pharmacies.\u003c\/p\u003e\n\n\u003ch3\u003ePatients Seeking Traditional Medicine\u003c\/h3\u003e\n\n\u003cp\u003eThe market for traditional medicine is significant in China. According to the \u003cstrong\u003eNational Center for Biotechnology Information\u003c\/strong\u003e, more than \u003cstrong\u003e60%\u003c\/strong\u003e of the Chinese population utilizes traditional Chinese medicine (TCM) in conjunction with conventional treatments. Yiling Pharmaceutical focuses on this growing demographic, providing products tailored for various ailments.\u003c\/p\u003e\n\n\u003cp\u003eIn 2022, the company reported that its sales from traditional medicine products accounted for approximately \u003cstrong\u003e45%\u003c\/strong\u003e of its total revenue, demonstrating a strong foothold in this segment. Products like Yiling's herbal remedies are specifically designed for patients interested in holistic healing options.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Professionals\u003c\/h3\u003e\n\n\u003cp\u003eHealthcare professionals, including doctors and pharmacists, represent a critical segment for Yiling Pharmaceutical. According to the \u003cstrong\u003eChina National Health Commission\u003c\/strong\u003e, there are over \u003cstrong\u003e3 million\u003c\/strong\u003e licensed healthcare professionals in China, increasing the potential reach for Yiling’s pharmaceutical offerings.\u003c\/p\u003e\n\n\u003cp\u003eYiling has developed strong relationships with healthcare professionals, which is vital for product endorsements and prescriptions. In recent reports, it was noted that healthcare professionals contributed to about \u003cstrong\u003e35%\u003c\/strong\u003e of the company’s annual sales, highlighting the importance of this customer segment.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\n\u003cp\u003eRetail pharmacies are essential distribution channels for Yiling Pharmaceutical. In 2023, the retail pharmacy market in China was valued at approximately \u003cstrong\u003e$60 billion\u003c\/strong\u003e, with an expected CAGR of \u003cstrong\u003e8%\u003c\/strong\u003e from 2023 to 2028, according to \u003cstrong\u003eMarket Research Future\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eYiling collaborates with over \u003cstrong\u003e1,500\u003c\/strong\u003e retail pharmacies nationwide, ensuring broad accessibility of its products. This segment accounted for about \u003cstrong\u003e20%\u003c\/strong\u003e of the company's overall revenue in 2022, highlighting its growing importance as a channel for traditional medicine products.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eKey Statistics\u003c\/th\u003e\n        \u003cth\u003eRevenue Contribution\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatients Seeking Traditional Medicine\u003c\/td\u003e\n        \u003ctd\u003eOver 60% of the population uses traditional medicine\u003c\/td\u003e\n        \u003ctd\u003e45% of total revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Professionals\u003c\/td\u003e\n        \u003ctd\u003e3 million licensed healthcare professionals\u003c\/td\u003e\n        \u003ctd\u003e35% of total revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n        \u003ctd\u003eMarket value: $60 billion, CAGR: 8%\u003c\/td\u003e\n        \u003ctd\u003e20% of total revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWith these segments, Yiling Pharmaceutical effectively tailors its value propositions to meet the specific needs of each group, ensuring a diverse and sustainable revenue stream.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eR\u0026amp;D Expenses\u003c\/h3\u003e\n\u003cp\u003eIn 2022, Shijiazhuang Yiling Pharmaceutical Co., Ltd. reported R\u0026amp;D expenses amounting to approximately \u003cstrong\u003eRMB 1.1 billion\u003c\/strong\u003e, representing about \u003cstrong\u003e10.5%\u003c\/strong\u003e of its total revenue. The company emphasizes innovation in traditional Chinese medicine and invests heavily in the development of new products, particularly in the areas of oncology and cardiovascular diseases. In 2021, R\u0026amp;D expenses were around \u003cstrong\u003eRMB 900 million\u003c\/strong\u003e, reflecting a year-over-year growth of over \u003cstrong\u003e22%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing costs for Shijiazhuang Yiling Pharmaceutical Co., Ltd. are significant, accounting for roughly \u003cstrong\u003e60%\u003c\/strong\u003e of total operating costs. In the fiscal year 2022, the total manufacturing expenses were approximately \u003cstrong\u003eRMB 3.2 billion\u003c\/strong\u003e. A substantial portion of these costs is attributed to raw materials, labor, and overhead. Notably, the cost of raw materials has increased by about \u003cstrong\u003e15%\u003c\/strong\u003e due to supply chain disruptions and rising global commodity prices.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCost Component\u003c\/th\u003e\n    \u003cth\u003e2022 (RMB Billion)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Costs\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRaw Materials\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1.5\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e46.9%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLabor\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1.0\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e31.3%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOverhead\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e0.7\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e21.9%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eMarketing and Distribution\u003c\/h3\u003e\n\u003cp\u003eMarketing and distribution costs for Shijiazhuang Yiling Pharmaceutical Co., Ltd. stood at around \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e in 2022, which is about \u003cstrong\u003e5.8%\u003c\/strong\u003e of total revenue. The company employs various strategies to reach its customers, including digital marketing, partnerships with healthcare providers, and participation in industry conferences. The distribution network covers more than \u003cstrong\u003e30 provinces\u003c\/strong\u003e in China and extends to international markets.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eDigital Marketing: Accounts for \u003cstrong\u003e40%\u003c\/strong\u003e of total marketing costs.\u003c\/li\u003e\n  \u003cli\u003eTraditional Advertising: Represents \u003cstrong\u003e30%\u003c\/strong\u003e of marketing expenses.\u003c\/li\u003e\n  \u003cli\u003eDistribution Costs: Include logistics and freight, totaling around \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e \n\n\u003cp\u003eIn recent years, the company has adopted a more aggressive marketing approach, increasing its budget by approximately \u003cstrong\u003e15%\u003c\/strong\u003e annually to enhance brand visibility and product reach.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eShijiazhuang Yiling Pharmaceutical Co., Ltd.\u003c\/strong\u003e generates revenue through multiple streams, primarily focusing on pharmaceutical products, licensing, and government contracts.\u003c\/p\u003e\n\n\u003ch3\u003eSales of Pharmaceutical Products\u003c\/h3\u003e\n\u003cp\u003eThe majority of Yiling's revenue comes from the sales of its pharmaceutical products. In the fiscal year 2022, Yiling reported total sales revenue of \u003cstrong\u003eRMB 5.8 billion\u003c\/strong\u003e, with pharmaceutical product sales contributing approximately \u003cstrong\u003e85%\u003c\/strong\u003e of that total. Key products include traditional Chinese medicine and modern formulations, with notable brands such as \u003cstrong\u003eShuanghuanglian\u003c\/strong\u003e and \u003cstrong\u003eYiqi Sisheng Decoction\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing and Royalties\u003c\/h3\u003e\n\u003cp\u003eLicensing agreements represent another significant source of revenue for Yiling. In 2022, licensing and royalty income amounted to approximately \u003cstrong\u003eRMB 400 million\u003c\/strong\u003e, accounting for \u003cstrong\u003e7%\u003c\/strong\u003e of total revenue. This includes partnerships with international firms to distribute Yiling's proprietary formulations in various markets, particularly in Southeast Asia and Europe.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Contracts\u003c\/h3\u003e\n\u003cp\u003eYiling also secures revenue through government contracts, which provide a stable income stream. In 2022, revenue from government contracts reached \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e, making up about \u003cstrong\u003e10%\u003c\/strong\u003e of the overall revenue. These contracts typically involve the supply of medicines and vaccines to public health sectors, showing Yiling's role in addressing national health needs.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSales of Pharmaceutical Products\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e4.93 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing and Royalties\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e400 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e7%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGovernment Contracts\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e600 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTotal\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e5.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45662204461205,"sku":"002603sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/002603sz-business-model-canvas.png?v=1739110344","url":"https:\/\/dcf-model.com\/pt\/products\/002603sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}